New treatment approaches in melanoma: Current research and clinical prospects

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 1, 2013, Pages 73-80

  Rughani, Milap G ^a   Gupta, Avinash ^a   Middleton, Mark R ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

clinical management; immunotherapy; melanoma; targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ALPHA INTERFERON; B RAF KINASE; CARBOPLATIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MK 3475; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NIVOLUMAB; PACLITAXEL; PEGINTERFERON ALPHA; PEPTIDE VACCINE; PLX 4072; PROTEIN ANTIBODY; SELUMETINIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; TICILIMUMAB; TRAMETINIB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CELL MEMBRANE PERMEABILITY; COLITIS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEVER; GENE MUTATION; GENE TARGETING; HEPATITIS; HUMAN; HYPOPHYSITIS; KERATOACANTHOMA; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 84877879078     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012463260     Document Type: Review

References (44)

1. Ascierto P. Marincola F. Ribas A. (2011) Anti-Ctla4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 9: 196.
2. Ascierto et al. (2012) Efficacy and safety of oral MEK 162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV 600 or NRAS mutations. J Clin Oncol 30: (suppl; abstr. 8511).
3. Ashida A. Takata M. Murata H. Kido K. Saida T. (2009) Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124: 862–868.
4. Atkins M. Kunkel L. Sznol M. Rosenberg S. (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl. 1): S11–S14
5. Atkins M. Middleton M. Chapman P. (2009) Chemotherapy-based treatment of metastatic melanoma. In: Ed. Atkins M. (ed.), Cutaneous Melanoma, 5th edn. St. Louis, MO: Quality Medical Publishing, Inc.
6. Birck A. Ahrenkiel V. Zeuthen J. Hou-Jensen K. Guldberg P. (2000) Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Investigative Dermatol 114: 277–280.
7. Brahmer J. Tykodi S. Chow L. Hwu W. Topalian S. Hwu P. et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, PMID: 22658128.
8. Carvajal R. Antonescu C. Wolchok J. Chapman P. Roman R. Teitcher J. et al. (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305: 2327–2334.
9. Chapman B. (2012) Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (Vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. Proc Amer Soc Clin Oncol, Abstract 8502.
10. Chapman P. Hauschild A. Robert C. Haanen J. Ascierto P. Larkin J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
11. Curtin J. Busam K. Pinkel D. Bastian B. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340–4346.
12. Davies M. Gershenwald J. (2011) Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am 20: 165–180.
13. Eggermont A. Suciu S. Santinami M. Testori A. Kruit W. Marsden J. et al. for EORTC Melanoma Group (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372: 117–126.
14. Flaherty K. Hodi F. Bastian B. (2010 a) Mutation-driven drug development in melanoma. Curr Opin Oncol 22: 178–183.
15. Flaherty K. Puzanov I. Kim K. Ribas A. McArthur G. Sosman J. et al. (2010 b) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809–819.
16. Flaherty K. Redlinger M. Schuchter L. Lathia C. Weber B. O'Dwyer P. (2005) Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol 23: 3037.
17. Flaherty K. Robert C. Hersey P. Nathan P. Garbe C. Milhem M. et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med, in press.
18. Flaherty K. Schiller J. Schuchter L. Liu G. Tuveson D. Redlinger M. et al. (2008) A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14: 4836–4842.
19. Garnett M. Marais R. (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313–319.
20. Goel V. Lazar A. Warneke C. Redston M. Haluska F. (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Investigative Dermatol 126: 154–160.
21. Guo J. Si L. Kong Y. Flaherty K. Xu X. Zhu Y. et al. (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring C-KIT mutation or amplification. J Clin Oncol 29: 2904–2909.
22. Hauschild A. Agarwala S. Trefzer U. Hogg D. Robert C. Hersey P. et al. (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27: 2823–2830.
23. Hauschild A. Grob J. Demidov L. Jouary T. Gutzmer R. Millward M. et al. (2012) Phase III, randomized, open-label, multicenter trial (Break-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF V600E -mutated melanoma. Proc Amer Soc Clin Oncol, Abstract LBA8500.
24. Heidorn S. Milagre C. Whittaker S. Nourry A. Niculescu-Duvas I. Dhomen N. et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209–221.
25. Hodi F. Friedlander P. Corless C. Heinrich M. MacRae S. Kruse A. et al. (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26: 2046–2051.
26. Janne et al. (2012) Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 30: (suppl; abstr. 7503).
27. Kirkwood J. Bastholt L. Robert C. Sosman J. Larkin J. Hersey P. et al. (2012) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18: 555–567.
28. Lorusso P. Adjei A. Varterasian M. Gadgeel S. Reid J. Mitchell D. et al. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23: 5281–5293.
29. Lutzky J. Bauer J. Bastian B. (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21: 492–493.
30. Mocellin et al. (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102: 493–501.
31. Nazarian R. Shi H. Wang Q. Kong X. Koya R. Lee H. et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–977.
32. Patnaik A. (2012) Phase I study of Mk-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Proc Amer Soc Clin Oncol, Abstract 2512.
33. Poulikakos P. Persaud Y. Janakiraman M. Kong X. Ng C. Moriceau G. et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387–390.
34. Rinehart J. Adjei A. Lorusso P. Waterhouse D. Hecht J. Natale R. et al. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456–4462.
35. Robert C. Thomas L. Bondarenko I. O'Day S. Weber J. Garbe C. et al. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med 364: 2517–2526.
36. Russo A. Torrisi E. Bevelacqua Y. Perrotta R. Libra M. McCubrey J. et al. (2009) Melanoma: molecular pathogenesis and emerging target therapies (review). Int J Oncol 34: 1481–1489.
37. Smalley Flaherty (2009) Integrating BRAF / MEK inhibitors into combination therapy for melanoma. Br J Cancer 100: 431–435.
38. Smalley K. Haass N. Brafford P. Lioni M. Flaherty K. Herlyn M. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Therapeut 5: 1136–1144.
39. Solit D. Garraway L. Pratilas C. Sawai A. Getz G. Basso A. et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358–362.
40. Sosman J. Kim K. Schuchter L. Gonzalez R. Pavlick A. Weber J. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707–714.
41. Stahl J. Sharma A. Cheung M. Zimmerman M. Cheng J. Bosenberg M. et al. (2004) Deregulated AKT 3 activity promotes development of malignant melanoma. Cancer Res 64: 7002–7010.
42. Topalian S. Hodi F. Brahmer J. Gettinger S. Smith D. McDermott D. et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, PMID: 22658127.
43. Wilhelm S. Carter C. Tang L. Wilkie D. McNabola A. Rong H. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109.
44. Wilmott J. Long G. Howle J. Haydu L. Sharma R. Thompson J. et al. (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18: 1386–1394.